Literature DB >> 7519892

Autocrine and paracrine roles for growth factors in melanoma.

I M Shih1, M Herlyn.   

Abstract

Distinct biologic and histopathological features characterizing each stage of tumor progression toward a more aggressive phenotype have been defined in the human melanocytic cell system. One of the most significant aspects accompanying melanoma progression is the acquisition of growth autonomy and the expression of multiple growth factors and receptors by tumor cells but not by normal melanocytes. Among the growth factors produced by melanoma cells, bFGF, TGF-alpha, TGF-beta, PDGF A and B chains, MGSA, and interleukins have been extensively characterized. The complex signaling networks mediated by these melanoma-derived factors are responsible for the autocrine growth stimulation of melanoma cells and for paracrine actions of growth factors in the generation of a microenvironment favorable for tumor survival and invasion. bFGF is the best characterized candidate for autocrine stimulation in melanoma cells. In addition, bFGF and other growth factors not apparently involved in autocrine loops have been shown to activate neighboring stromal cells and to participate in angiogenesis, fibrous stroma formation, activation of proteolytic enzymes produced by normal cells, promotion of adhesive interactions between tumor cells and extracellular matrix and endothelium, and suppression of local immunity. Experimental models that can account for the complex interactions between normal and tumor cells are needed to further explore the roles of autocrine and paracrine actions of growth factors and their receptors in melanoma development and progression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519892

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  20 in total

1.  Effect of fibroblast growth factor saporin mitotoxins on human bladder cell lines.

Authors:  T A Tetzke; M C Caton; P A Maher; Z Parandoosh
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

2.  A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma.

Authors:  Xiaoping Zhang; Neng-Lian Li; Chao Guo; Ying-Dong Li; Lu-Lu Luo; Yong-Qi Liu; Yun-Yan Duan; Zhen-Dong Li; Xiao-Rong Xie; Hai-Xia Song; Li-Ping Yang; Fang-Yu An
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

3.  Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.

Authors:  Kerrington R Molhoek; Amber L Shada; Mark Smolkin; Sudhir Chowbina; Jason Papin; David L Brautigan; Craig L Slingluff
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

4.  Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin.

Authors:  C Berking; R Takemoto; K Satyamoorthy; R Elenitsas; M Herlyn
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

Review 5.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

6.  The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis.

Authors:  Gong Yang; Daniel G Rosen; Zhihong Zhang; Robert C Bast; Gordon B Mills; Justin A Colacino; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-23       Impact factor: 11.205

7.  Stem cell factor affects tumour progression markers in metastatic melanoma cells.

Authors:  Francesca Prignano; Gianni Gerlini; Benedetta Salvatori; Claudio Orlando; Sandra Mazzoli; Nicola Pimpinelli; Silvia Moretti
Journal:  Clin Exp Metastasis       Date:  2006-09-22       Impact factor: 5.150

Review 8.  Nf-kappa B, chemokine gene transcription and tumour growth.

Authors:  Ann Richmond
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

9.  PDGF-A promoter and enhancer elements provide efficient and selective antineoplastic gene therapy in multiple cancer types.

Authors:  A Mishra; A K Ormerod; M L Cibull; B T Spear; S D Kraner; D M Kaetzel
Journal:  Cancer Gene Ther       Date:  2008-11-07       Impact factor: 5.987

10.  Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

Authors:  Cindy S Hwang; Victor G Prieto; Abdul H Diwan; Gregory Lizee; Julie A Ellerhorst; Suhendan Ekmekcioglu; Ping Liu; Omar Eton; Sandra A Kinney; Elizabeth A Grimm; Patrick Hwu; Kevin B Kim
Journal:  Melanoma Res       Date:  2008-08       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.